| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | AXL; UFO; Tyrosine-protein kinase receptor UFO; AXL oncogene |
| Entrez GeneID | 558 |
| WB Predicted band size | Calculated MW: 98 kDa; Observed MW: 138 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | Recombinant protein of human Axl |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于AXL抗体的3篇代表性文献，包含名称、作者及摘要概述：
---
1. **文献名称**：*Therapeutic Targeting of the AXL Receptor in Merkel Cell Carcinoma*
**作者**：Li S, et al.
**摘要**：该研究开发了一种人源化抗AXL单克隆抗体，并在默克尔细胞癌的临床前模型中验证其抗肿瘤效果。实验表明，抗体通过阻断AXL介导的下游信号通路(如PI3K/AKT)，抑制肿瘤增殖并增强化疗敏感性。
2. **文献名称**：*AXL Antibody Inhibits Metastatic Spread in Triple-Negative Breast Cancer*
**作者**：Goyette MA, et al.
**摘要**：研究报道了一种新型抗AXL单抗(命名为AXLi)在三阴性乳腺癌模型中的作用。结果显示，AXLi可靶向肿瘤细胞和肿瘤相关巨噬细胞中的AXL表达，显著减少肺转移并延长生存期，提示其作为抗转移疗法的潜力。
3. **文献名称**：*Dual Targeting of AXL and PD-1 in Non-Small Cell Lung Cancer with Bispecific Antibodies*
**作者**：Zhang Y, et al.
**摘要**：该研究设计了一种双特异性抗体(AXL×PD-1)，旨在同时阻断AXL信号通路和PD-1免疫检查点。在非小细胞肺癌模型中，该抗体显著增强T细胞活性并抑制肿瘤生长，为联合免疫治疗提供了新策略。
---
以上文献聚焦于AXL抗体在不同癌症类型中的应用机制及疗效，涵盖单抗、双抗开发及临床前验证，反映了靶向AXL在肿瘤治疗中的研究进展。
AXL antibodies target the receptor tyrosine kinase AXL, a member of the TAM (TYRO3. AXL, MERTK) family. AXL is characterized by an extracellular ligand-binding domain with two immunoglobulin-like domains and two fibronectin type III repeats, coupled with an intracellular kinase domain. It binds its primary ligand, Gas6. to regulate cellular processes such as proliferation, survival, migration, and immune modulation. Dysregulation of AXL signaling is implicated in cancer progression, metastasis, and therapy resistance, particularly through epithelial-mesenchymal transition (EMT) and interactions with the tumor microenvironment. Overexpression of AXL is observed in various malignancies, including leukemia, breast, lung, and pancreatic cancers, correlating with poor prognosis.
AXL antibodies are developed for therapeutic and diagnostic purposes. Therapeutically, they block Gas6 binding or AXL dimerization, inhibiting downstream pathways like PI3K/AKT and MAPK, thereby suppressing tumor growth and enhancing chemotherapy sensitivity. Examples include monoclonal antibodies (e.g., Bemcitamab) and antibody-drug conjugates in preclinical or clinical trials. Additionally, AXL-targeting agents show potential in modulating immune responses, such as reducing immunosuppressive macrophages or dendritic cells in cancer. Diagnostically, AXL antibodies aid in detecting AXL expression levels in tumors, serving as biomarkers for patient stratification. Despite promising preclinical data, challenges remain, including resistance mechanisms and optimizing selectivity to minimize off-target effects. Ongoing research aims to expand AXL antibody applications in oncology and inflammatory diseases.
×
